CCCC
NASDAQC4 Therapeutics Inc.
Price$3.71+0.23 (+6.47%)
01:30 PM07:45 PM
News · 26 weeks51+300%
2026-01-182026-07-12
Mix2490d
- Insider12(50%)
- SEC Filings7(29%)
- Other5(21%)
Latest news
25 items- INSIDERChief Medical Officer Reyno Leonard converted options into 15,325 shares and covered exercise/tax liability with 7,397 shares, increasing direct ownership by 2% to 372,406 units (SEC Form 4) (for tax liability)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERDirector Grogan Donna Roy was granted 3,341 shares, increasing direct ownership by 5% to 74,853 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERDirector Anderson Kenneth Carl was granted 2,650 shares, increasing direct ownership by 4% to 71,950 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Hughes Owen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoerter Steven L.4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Koppikar Utpal4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooper Ronald Harold Wilfred4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Bessen Laura4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Fawell Stephen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory PopulationAt the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or Tolerability Data Further Support Development Strategy Across Lines of Therapy and in Combination With Approved Therapies, Positioning Cemsidomide as a Potential Foundational Therapy for Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradati
- INSIDERDirector Anderson Kenneth Carl exercised 1,070 shares at a strike of $2.11, increasing direct ownership by 2% to 69,300 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- PRC4 Therapeutics to Participate in Upcoming ConferencesWATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences. TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Management will participate in a virtual fireside chat on May 26, 2026, at 2:30 pm ET. 2026 Jefferies Global Healthcare Conference Management will participate in a fireside chat on June 3, 2026, at 8:45 am ET, taking place in New York, New York. Goldman Sachs 47th Annual Global Healthcare Conference Management will participate in 1x
- PRC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on May 18, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Ru
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form 10-Q filed by C4 Therapeutics Inc.10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsProgressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027 Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates Cash, Cash Equivalents and Marketable Securities of $268.3 Million as of March 31, 2026 with Cash Runway to the End of 2028 WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4
- SECSEC Form DEFA14A filed by C4 Therapeutics Inc.DEFA14A - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form DEF 14A filed by C4 Therapeutics Inc.DEF 14A - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
CCCC FAQ
7 questionsWhat does C4 Therapeutics Inc. do?
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors...Where does CCCC stock trade?
C4 Therapeutics Inc. (CCCC) is listed on NASDAQ.What sector and industry is CCCC in?
C4 Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did C4 Therapeutics Inc. go public?
C4 Therapeutics Inc. (CCCC) completed its IPO in 2020.What are analysts saying about CCCC?
C4 Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2025-12-02. Recent price targets range from $400.00 to $1200.00.What companies are similar to CCCC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CCCC side-by-side with any of them on Quantisnow.How can I track CCCC on Quantisnow?
Quantisnow aggregates C4 Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCCC to receive live email and push alerts on every new disclosure.